These are the stocks posting the largest moves before the bell.Market Insiderread more
More and more American firms are calling for the Trump administration to resolve its conflict with China.World Economyread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
Target CEO Brian Cornell apologized to customers for a disappointing weekend after the company experienced outages that shut down its cash registers and credit-card processors...Retailread more
Facebook's new cryptocurrency project, titled Libra and backed by the likes of Visa and Booking Holdings, is being widely embraced by market watchers.Trading Nationread more
American Airlines is ordering Airbus' new A321XLR, according to a source familiar with details of the agreement.Paris Air Showread more
The pilots union for Southwest Airlines says it will ask Boeing for compensation to cover legal costs and lost income for pilots due to the 737 Max grounding.Airlinesread more
Huawei CEO Ren Zhengfei tells CNBC the company's business is still strong in China.Technologyread more
U.S. President Donald Trump officially kicked off his reelection campaign Tuesday at a Florida rally where he exhorted thousands of rollicking supporters to keep advancing his...Politicsread more
But BlackRock's global fixed income chief also says he doesn't think the Fed will announce a rate cut until July.Market Insiderread more
Panera Bread has been testing a menu specifically for dinner and plans to expand the pilot to a new market next month.Restaurantsread more
U.S. drugmaker said on Tuesday it would lay off about 20 percent of its global workforce in an effort to cut spending.
The company had about 3,100 full-time employees worldwide as of the end of last year.
As part of the restructuring, Alexion will close some of its manufacturing sites, including its Rhode Island facility, the company said on a call with analysts.
The drugmaker also said it would relocate its headquarters to Boston from New Haven, Connecticut by mid-2018.
Alexion has been roiled in recent months by a sales practices scandal related to its pricey rare disease treatment Soliris as well as senior management resignations.
The company's chief executive officer and chief financial officer resigned in December, a month after Alexion announced it was investigating allegations related to its sales practices.
Alexion named long-time finance chief Paul Clancy as CFO in June, as newly appointed Alexion CEO Ludwig Hantson stepped up efforts to regain investor confidence.
Alexion said it expects to cut costs by $270 million each year by 2019, on a pre-tax, adjusted basis.
It expects pre-tax expenses of $340 million to $440 million related to the restructuring.
Alexion shares were down over 1 percent at $141.32 per share in midday trading on Tuesday.